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CORRESPONDENCE
Letters to the Editor
The CAPRIE-Like Subgroups of
CHARISMA: A CAPRIEciously
Biased Analysis of an
unCHARISMAtic Truth
In a textbook example of an improper subgroup analysis (1) (one
defined by events subsequent to randomization, in this case
fabricating new “CAPRIE [Clopidogrel Versus Aspirin in Patients
at Risk of Ischemic Events]-like” inclusion criteria), Bhatt et al. (2)
present data suggesting that persons with a prior history of stroke,
myocardial infarction (MI), or peripheral vascular disease (PVD)
may benefit from long-term dual antiplatelet therapy with aspirin
plus clopidogrel versus aspirin alone. It is illuminating to examine
this analysis in the historical and statistical context of the clinical
trial evidence from which it was derived.
In the CAPRIE trial (3), a trial twice as large as this “CAPRIE-
like” CHARISMA (Clopidogrel for High Atherothrombotic Risk,
Ischemic Stabilization, Management, and Avoidance) subgroup, a
marginally statistically significant result (p  0.043) was observed
for the primary end point, with statistical heterogeneity of treat-
ment effect (p  0.042) being observed between the 3 predefined
subgroups of patients with recent stroke, MI, or PVD. Only the
PVD subgroup benefited from the use of clopidogrel versus
aspirin. Despite statistically stronger evidence of heterogeneity of
(p  0.042) than of overall treatment effect (p  0.043), the
CAPRIE trial’s authors concluded that their hypothesis of univer-
sal superiority of clopidogrel over aspirin for all vascular disease
was correct anyway and presented in their primary manuscript
another improper post hoc subgroup analysis designed to make
their data comply with their hypothesis. Specifically, they analyzed
patients with newly fabricated inclusion criteria of any prior history
of coronary artery disease and, unlike the actual CAPRIE trial MI
patient subgroup, showed a statistically significant reduction in
recurrent vascular events.
History has now repeated itself. The most statistically signifi-
cant results presented in the primary CHARISMA trial report (4)
were excessive “moderate” bleeding events in the dual-therapy
group (p  0.001) and excess cardiovascular mortality in the
predefined primary prevention subcohort (p  0.01) treated with
dual therapy. The primary end point was negative. Ironically, and
perhaps predictably, 10 years after the CAPRIE trial, the
CHARISMA trial’s authors have suddenly selectively embraced
the value of heterogeneity of treatment effect (between the primary
and secondary prevention subcohorts) statistically evident in the
CHARISMA trial (p  0.045), using it as a philosophical
springboard to manipulate the data of the CHARISMA trial to fit
their hypothesis of the universal superiority of clopidogrel (this
time when combined with aspirin) over aspirin via the currently
published analysis.
Positive subgroups within negative trials such as the
CHARISMA trial are virtually always the result of confounding or
bias, especially post hoc defined subgroups. How many additional
unpublished subgroup analyses of the CHARISMA trial have
been performed? Are we to ignore the results of the MATCH
(Management of Atherothrombosis With Clopidogrel in High-
Risk Patients) trial (5), which showed statistically significant net
harm for patients with recent stroke/transient ischemic attack
(TIA) treated with clopidogrel plus aspirin versus clopidogrel
alone, in favor of those of an improper post hoc subgroup analysis
with less than one-half of the analogous patient population? No
clinical trial has ever shown superiority of clopidogrel, plus or
minus aspirin, over aspirin or clopidogrel alone for preventing
recurrent vascular events in patients with recent or remote history
of stroke/TIA.
If a randomized trial of aspirin plus clopidogrel versus aspirin
alone in a population of patients with any prior history of stroke,
MI, and/or PVD is performed, I predict it will show no statistically
significant net benefit.
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Reply
Dr. Gebel takes issue with our recent subgroup analysis of the
CHARISMA (Clopidogrel for High Atherothrombotic Risk,
Ischemic Stabilization, Management, and Avoidance) study,
which he labels improper because he incorrectly believes it was
defined by events that occurred after randomization (1,2). In fact,
the subgroup consisted of patients with documented ischemic
Journal of the American College of Cardiology Vol. 50, No. 17, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
Published by Elsevier Inc.
